Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Apr;18(4):792-804.
doi: 10.1038/s41423-020-00555-x. Epub 2020 Sep 30.

Clinical development of CAR T cell therapy in China: 2020 update

Jianshu Wei #  1 , Yelei Guo #  1 , Yao Wang #  1 , Zhiqiang Wu #  1 , Jian Bo  2 , Bin Zhang  3 , Jun Zhu  4 , Weidong Han  5
Affiliations
Review

Clinical development of CAR T cell therapy in China: 2020 update

Jianshu Wei et al. Cell Mol Immunol. 2021 Apr.

Abstract

Chimeric antigen receptor (CAR) T-cell therapy has achieved significant success in the treatment of hematological malignancies. In recent years, fast-growing CAR T clinical trials have actively explored their potential application scenarios. According to the data from the clinicaltrials.gov website, China became the country with the most registered CAR T trials in September 2017. As of June 30, 2020, the number of registered CAR T trials in China has reached 357. In addition, as many as 150 other CAR T trials have been registered on ChiCTR. Although CAR T therapy is flourishing in China, there are still some problems that cannot be ignored. In this review, we aim to systematically summarize the clinical practice of CAR T-cell therapy in China. This review will provide an informative reference for colleagues in the field, and a better understanding of the history and current situation will help us more reasonably conduct research and promote cooperation.

Keywords: China; chimeric antigen receptor; clinical trials.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests. I, Weidong Han, the corresponding author of this paper, certify that the contribution and competing interests statements included in this paper are correct and have been approved by all coauthors.

Figures

Fig. 1
Fig. 1
a Annual changes in the number of registered CAR T clinical trials and the phases of current trials. b Current registered CAR T trials for hematologic malignancies in China. c Current registered CAR T trials for solid tumors in China
Fig. 2
Fig. 2
a Annual changes in the number of published reports on CAR T therapy. b Current published reports of CAR T therapy on different targets in China. c Regional distribution of current published reports of CAR T therapy in China
See this image and copyright information in PMC

References

    1. Grupp SA, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N. Engl. J. Med. 2013;368:1509–1518. - PMC - PubMed
    1. Neelapu SS, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N. Engl. J. Med. 2017;377:2531–2544. - PMC - PubMed
    1. Schuster SJ, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N. Engl. J. Med. 2019;380:45–56. - PubMed
    1. Schuster SJ, et al. Chimeric antigen receptor T cells in refractory B-cell lymphomas. N. Engl. J. Med. 2017;377:2545–2554. - PMC - PubMed
    1. Axicabtagene ciloleucel (Yescarta) for B-cell lymphoma. Med. Lett. Drugs Ther.60:e122–e123 (2018). - PubMed

Publication types

MeSH terms

Substances